Product information sheet

January 2017

Imatinib-Trima 100mg, Film coated tablets

Manufacturer:	Trima Pharmaceutical Products
	Maabarot Ltd., Israel
Dossier status:	Complete CTD file
Dossier date:	Dossier ready, submitted to Israeli MOH in 07/2015 and approved Dec 2016.
<u>Dosage form:</u>	Film-coated tablets

Bioequivalence reference:

A bio waiver was granted based on the BE study conducted for Imatinib-Trima 400mg film coated tablets.

Stability data:

Packaging:

3 batches, 3 months at 40°C, 75% RH 3 batches, 3 years at 25°C, 60% RH Tablets are packed in Alu/PVC blisters of 10 tablets/blister.

The European Union (EU) has in place an agreement (2013/1/EU) on conformity assessment and mutual acceptance of Pharmaceutical Good Manufacturing Practice (GMP) with Israel. The Trima manufacturing facility is therefore considered as EU-GMP compliant.

For further information, please contact:

Products protected by patents in force are neither offered for sale nor marketed in jurisdictions where such activities would constitute patent infringement. $\mathbf{I} \underset{C}{\mathbf{N}} \mathbf{T} \underset{N}{\mathbf{T}} \underset{S}{\mathbf{E}} \mathbf{R} \underset{U}{\mathbf{P}} \underset{L}{\mathbf{T}} \underset{A}{\mathbf{N}} \underset{C}{\mathbf{N}} \mathbf{R} \underset{V}{\mathbf{M}}$

Peter Wittner B.Sc Direct line: +972 58 773 4238 E-mail:peter@interpharm-consultancy.co.uk web:www.interpharm-consultancy.co.uk

9c Szold Street, Raanana, Israel 43218 Phone: +44 20 8446 5572